Efficacy and safety of 28‐day treatment with oral insulin ( <scp>ORMD</scp> ‐0801) in patients with type 2 diabetes: A randomized, placebo‐controlled trial

In patients with T2D, bedtime ORMD-0801 curbed increases in night-time glycaemia, 24-hour glycaemia and HbA1c, without increasing the risk of hypoglycaemia or safety events compared with the control arm.